Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Published

Journal Article

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Full Text

Duke Authors

Cited Authors

  • Tallman, MS; Wang, ES; Altman, JK; Appelbaum, FR; Bhatt, VR; Bixby, D; Coutre, SE; De Lima, M; Fathi, AT; Fiorella, M; Foran, JM; Hall, AC; Jacoby, M; Lancet, J; LeBlanc, TW; Mannis, G; Marcucci, G; Martin, MG; Mims, A; O'Donnell, MR; Olin, R; Peker, D; Perl, A; Pollyea, DA; Pratz, K; Prebet, T; Ravandi, F; Shami, PJ; Stone, RM; Strickland, SA; Wieduwilt, M; Gregory, KM; OCN, ; Hammond, L; Ogba, N

Published Date

  • June 1, 2019

Published In

Volume / Issue

  • 17 / 6

Start / End Page

  • 721 - 749

PubMed ID

  • 31200351

Pubmed Central ID

  • 31200351

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2019.0028

Language

  • eng

Conference Location

  • United States